These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 24308685)

  • 1. Optimal management of elderly patients with myeloma.
    Cerrato C; Mina R; Palumbo A
    Expert Rev Anticancer Ther; 2014 Feb; 14(2):217-28. PubMed ID: 24308685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
    Palumbo A; Mateos MV; Bringhen S; San Miguel JF
    Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial treatment of nontransplant patients with multiple myeloma.
    Cerrato C; Palumbo A
    Semin Oncol; 2013 Oct; 40(5):577-84. PubMed ID: 24135402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations.
    Maes H; Delforge M
    Expert Rev Hematol; 2015 Jun; 8(3):355-66. PubMed ID: 25739703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
    Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of myeloma--state of the art.
    Harousseau JL
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How lenalidomide is changing the treatment of patients with multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S23-35. PubMed ID: 23816163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of thalidomide in the treatment of patients with multiple myeloma.
    Morgan GJ; Davies FE
    Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S14-22. PubMed ID: 23827438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential or combination therapy for multiple myeloma.
    Nooka A; Lonial S
    Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.